

**Table 2**  
**Hematology for SD rats treated with 2-MF for 4 weeks**

Item		Male				Female			
		Control	3 mg/kg	10 mg/kg	30 mg/kg	Control	3 mg/kg	10 mg/kg	30 mg/kg
WBC	/μL	6680 ± 295	6400 ± 908	5460 ± 541*	5840 ± 650	4300 ± 1221	4560 ± 833	4520 ± 823	5280 ± 432
RBC	/μL	777 ± 27	766 ± 35	767 ± 14	796 ± 20	783 ± 22	761 ± 12	763 ± 29	776 ± 20
Hb	g/dL	14.6 ± 0.4	14.4 ± 0.6	14.1 ± 0.4	14.0 ± 0.5	15.0 ± 0.4	14.5 ± 0.3	14.4 ± 0.5	13.9 ± 0.5**
Ht	%	40.9 ± 0.7	40.4 ± 1.6	39.7 ± 0.8	39.6 ± 0.9	41.4 ± 0.9	40.1 ± 1.0	40.6 ± 1.4	39.4 ± 1.3*
MCV	fL	52.6 ± 1.1	52.8 ± 1.3	51.8 ± 0.8	50.0 ± 0.0	53.2 ± 0.8	52.6 ± 0.5	53.2 ± 0.8	50.8 ± 0.8**
MCH	pg	18.8 ± 0.3	18.8 ± 0.5	18.3 ± 0.4	17.7 ± 0.2**	19.2 ± 0.1	19.0 ± 0.3	18.9 ± 0.2	17.9 ± 0.2**
MCHC	%	35.6 ± 0.4	35.6 ± 0.3	35.4 ± 0.4	35.4 ± 0.3	36.3 ± 0.4	36.0 ± 0.3	35.5 ± 0.2**	35.2 ± 0.3**
Plt	x10 <sup>4</sup> /μL	82.8 ± 9.2	100.2 ± 7.8**	94.3 ± 4.6*	105.4 ± 5.5**	92.7 ± 12.0	93.7 ± 3.8	94.8 ± 4.0	86.9 ± 5.2
Reticulocyte	%	54.0 ± 7.8	51.8 ± 6.9	54.4 ± 3.2	54.0 ± 5.8	40.2 ± 6.9	40.0 ± 5.1	36.8 ± 4.0	40.8 ± 3.1
Neutro	%	18.8 ± 5.6	17.9 ± 1.3	20.5 ± 6.5	19.2 ± 2.6	20.5 ± 6.6	17.3 ± 1.5	16.9 ± 4.4	18.4 ± 4.5
Lympho	%	77.1 ± 6.1	77.7 ± 1.7	74.1 ± 6.5	76.7 ± 3.0	75.7 ± 6.7	78.4 ± 1.9	80.8 ± 5.1	78.5 ± 4.4
Mono	%	2.5 ± 0.6	3.3 ± 0.9	4.0 ± 0.4*	3.2 ± 1.0	2.5 ± 1.6	2.8 ± 0.7	1.5 ± 0.6	2.0 ± 0.7
Eosino	%	1.6 ± 0.6	1.2 ± 0.5	1.4 ± 0.3	0.9 ± 0.3	1.3 ± 0.4	1.4 ± 0.4	0.9 ± 0.4	1.0 ± 0.3
Baso	%	0.1 ± 0.1	0.0 ± 0.0	0.0 ± 0.0	0.0 ± 0.0	0.0 ± 0.0	0.0 ± 0.0	0.0 ± 0.0	0.0 ± 0.0

\*,\*\*: Significantly different from the control group at  $p < 0.05$  and  $0.01$ , respectively.

**Table 3**  
**Serum biochemistry for SD rats treated with 2-MF for 4 weeks**

Item	Male				Female			
	Control	3 mg/kg	10 mg/kg	30 mg/kg	Control	3 mg/kg	10 mg/kg	30 mg/kg
TP g/dL	5.6 ± 0.1	5.4 ± 0.2*	5.4 ± 0.1	5.6 ± 0.1	6.1 ± 0.4	6.2 ± 0.4	6.5 ± 0.2	6.6 ± 0.3*
Albumin g/dL	4.1 ± 0.1	4.0 ± 0.1	4.1 ± 0.1	4.3 ± 0.1*	4.6 ± 0.3	4.9 ± 0.3	5.1 ± 0.1*	5.3 ± 0.3**
T-Bil mg/dL	0.0 ± 0.0	0.0 ± 0.1	0.1 ± 0.0	0.1 ± 0.0	0.1 ± 0.1	0.1 ± 0.0	0.1 ± 0.1	0.1 ± 0.0
AST IU/L	87.4 ± 14.7	90.0 ± 20.0	91.0 ± 18.1	94.6 ± 20.3	88.6 ± 15.8	88.2 ± 17.3	72.6 ± 6.4	86.4 ± 26.8
ALT IU/L	46.2 ± 4.1	45.2 ± 5.9	44.0 ± 10.2	47.0 ± 6.0	43.6 ± 12.0	39.8 ± 9.8	30.0 ± 4.2	32.8 ± 6.6
LD IU/L	841.4 ± 81.1	759.8 ± 114.5	956.8 ± 205.8	934.4 ± 67.8	752.6 ± 222.8	908.2 ± 218.3	697.6 ± 248.8	551.8 ± 313.4
ALP IU/L	1226.8 ± 263.0	1120.8 ± 227.6	868.0 ± 79.4*	1050.8 ± 157.1	620.2 ± 100.2	466.8 ± 19.6	503.4 ± 96.1	583.6 ± 182.0
γ-GTP IU/L	1.0 ± 0.0	1.0 ± 0.0	1.0 ± 0.0	2.0 ± 0.7	1.0 ± 0.0	1.0 ± 0.0	1.4 ± 0.5	2.8 ± 0.8**
CPK IU/L	547.6 ± 35.7	544.4 ± 70.1	583.0 ± 165.5	603.6 ± 48.4	494.0 ± 128.6	575.6 ± 165.0	446.2 ± 196.3	374.4 ± 182.8
CRNN mg/dL	0.3 ± 0.0	0.3 ± 0.0	0.3 ± 0.1	0.2 ± 0.0*	0.3 ± 0.0	0.3 ± 0.0	0.3 ± 0.1	0.2 ± 0.0**
BUN mg/dL	12.6 ± 1.5	14.0 ± 1.2	13.0 ± 1.0	13.2 ± 1.9	12.8 ± 1.9	13.4 ± 1.8	13.6 ± 0.9	13.2 ± 1.5
Glucose mg/dL	133.4 ± 21.4	124.4 ± 9.6	110.2 ± 5.9	91.0 ± 6.0*	124.8 ± 10.9	119.2 ± 18.9	116.4 ± 9.1	112.4 ± 6.2
TG mg/dL	50.6 ± 11.5	39.8 ± 9.3	30.8 ± 7.7*	47.4 ± 17.4	38.2 ± 15.7	41.6 ± 6.8	47.8 ± 15.2	80.8 ± 19.7**
T-Cho mg/dL	56.0 ± 10.2	63.2 ± 2.6	55.0 ± 6.7	73.4 ± 12.8*	82.4 ± 5.4	73.8 ± 5.4	79.6 ± 4.9	94.2 ± 14.6
Na mEq/L	145.6 ± 0.5	144.6 ± 0.5	144.6 ± 0.9	145.8 ± 0.4	145.4 ± 0.9	145.4 ± 0.5	146.8 ± 1.1	145.6 ± 0.9
K mEq/L	4.6 ± 0.2	4.8 ± 0.2	5.0 ± 0.1**	4.9 ± 0.1*	4.8 ± 0.1	4.7 ± 0.2	4.6 ± 0.1	4.5 ± 0.1
Cl mEq/L	106.0 ± 0.7	105.6 ± 0.9	106.2 ± 0.8	106.0 ± 0.7	107.2 ± 0.8	106.2 ± 1.9	106.8 ± 1.6	105.0 ± 1.2
Ca mg/dL	9.5 ± 0.1	9.6 ± 0.2	9.7 ± 0.2	9.9 ± 0.2**	9.9 ± 0.3	10.2 ± 0.3	10.5 ± 0.1*	10.7 ± 0.4**
IP mg/dL	7.4 ± 0.1	7.7 ± 0.4	7.8 ± 0.3	8.7 ± 0.3**	7.0 ± 0.6	7.4 ± 0.6	7.8 ± 0.3*	7.4 ± 0.2

\*, \*\*: Significantly different from the control group at  $p < 0.05$  and  $0.01$ , respectively.

**Table 4**  
**Hematology for SD *gpt* delta rats treated with 2-MF for 13 weeks**

Item		Male				Female			
		0 mg/kg	1.2 mg/kg	6 mg/kg	30 mg/kg	0 mg/kg	1.2 mg/kg	6 mg/kg	30 mg/kg
WBC	/μL	49.5 ± 10.8	55.7 ± 10.7	52.1 ± 11.1	47.1 ± 13.0	27.1 ± 8.1	33.3 ± 9.0	33.0 ± 5.5	34.0 ± 7.4
RBC	/μL	850.4 ± 51.5	846.3 ± 45.1	844.6 ± 50.3	845.4 ± 33.1	683.0 ± 42.4	705.0 ± 42.3	685.9 ± 28.4	693.9 ± 94.2
Hb	g/dL	15.0 ± 0.6	14.9 ± 0.8	14.7 ± 0.5	14.1 ± 0.6*	14.1 ± 0.6	14.6 ± 0.3*	14.2 ± 0.5	13.4 ± 0.5**
Ht	%	47.2 ± 2.1	47.3 ± 2.5	47.0 ± 2.4	45.9 ± 2.1	40.7 ± 2.1	41.9 ± 1.7	40.2 ± 1.7	39.3 ± 1.8
MCV	fl	55.5 ± 1.2	55.9 ± 1.1	55.7 ± 0.8	54.2 ± 1.2*	59.7 ± 1.8	56.6 ± 8.7	58.6 ± 1.1	54.4 ± 1.3**
MCH	pg	17.6 ± 0.7	17.6 ± 0.4	17.4 ± 0.8	16.6 ± 0.6**	20.7 ± 0.9	20.8 ± 1.0	20.8 ± 0.7	18.6 ± 0.7**
MCHC	%	31.7 ± 0.6	31.6 ± 0.4	31.3 ± 1.0	30.7 ± 0.8*	34.6 ± 1.0	34.9 ± 0.9	35.4 ± 1.0	34.2 ± 0.9
Plt	x10 <sup>4</sup> /μL	103.1 ± 16.2	95.0 ± 9.6	99.8 ± 12.8	118.5 ± 19.0	122.5 ± 16.1	124.7 ± 21.4	134.2 ± 11.4	129.9 ± 17.8
<i>Differential WBC counts</i>									
Band	%	0.7 ± 1.2	0.3 ± 0.3	0.4 ± 0.5	0.3 ± 0.3	0.2 ± 0.3	0.4 ± 0.3	0.3 ± 0.4	0.2 ± 0.2
Seg	%	29.5 ± 6.8	30.2 ± 5.8	29.4 ± 7.3	33.6 ± 4.9	26.1 ± 3.3	30.3 ± 9.4	28.7 ± 5.3	28.8 ± 4.6
Eosi	%	2.2 ± 1.1	3.1 ± 1.1	3.1 ± 1.5	2.1 ± 1.1	3.0 ± 1.5	2.6 ± 1.3	2.9 ± 1.0	2.4 ± 1.4
Baso	%	0.1 ± 0.2	0.0 ± 0.0	0.0 ± 0.0	0.0 ± 0.0	0.2 ± 0.5	0.2 ± 0.3	0.0 ± 0.0	0.0 ± 0.0
Lymph	%	67.0 ± 7.6	66.4 ± 5.7	67.1 ± 6.3	64.0 ± 5.2	69.8 ± 4.3	66.0 ± 10.1	67.9 ± 6.1	68.4 ± 4.3
Mono	%	0.3 ± 0.4	0.1 ± 0.2	0.0 ± 0.0	0.1 ± 0.3	0.7 ± 0.6	0.6 ± 0.4	0.4 ± 0.5	0.2 ± 0.2
Ebl	/200 WBC	0.8 ± 1.1	0.6 ± 0.7	0.2 ± 0.4	0.6 ± 0.7	0.4 ± 0.7	0.6 ± 0.7	0.5 ± 0.5	0.6 ± 0.5

\*,\*\*: Significantly different from the control group at  $p < 0.05$  and  $0.01$ , respectively.

**Table 5**  
**Serum biochemistry for SD *gpt* delta rats treated with 2-MF for 13 weeks**

Item	Male				Female			
	0 mg/kg	1.2 mg/kg	6 mg/kg	30 mg/kg	0 mg/kg	3 mg/kg	10 mg/kg	30 mg/kg
TP g/dL	6.0 ± 0.3	6.1 ± 0.4	6.1 ± 0.2	6.2 ± 0.3	7.0 ± 0.6	6.7 ± 0.3	6.9 ± 0.4	7.3 ± 0.3
Albumin g/dL	4.2 ± 0.2	4.3 ± 0.2	4.5 ± 0.1	4.6 ± 0.3*	5.2 ± 0.5	5.2 ± 0.3	5.5 ± 0.3	5.7 ± 0.2*
T-Bil mg/dL	0.0 ± 0.1	0.0 ± 0.0	0.1 ± 0.1	0.1 ± 0.0*	0.1 ± 0.1	0.0 ± 0.1	0.0 ± 0.1	0.1 ± 0.0*
AST IU/L	75.6 ± 8.4	72.8 ± 12.3	72.8 ± 8.6	84.6 ± 21.7	70.9 ± 11.3	65.1 ± 18.2	64.0 ± 12.5	64.9 ± 13.1
ALT IU/L	42.8 ± 4.0	38.8 ± 7.1	32.6 ± 4.0*	27.4 ± 4.2**	36.2 ± 4.9	32.9 ± 4.1	30.6 ± 2.9*	21.9 ± 4.9**
LD IU/L	904.2 ± 92.6	834.6 ± 201.2	976.6 ± 188.3	1183.0 ± 362.7	691.3 ± 113.6	605.5 ± 144.9	698.9 ± 188.2	782.9 ± 234.1
ALP IU/L	428.6 ± 40.8	485.6 ± 64.8	486.8 ± 89.8*	566.2 ± 38.9**	232.7 ± 60.1	256.5 ± 92.6	198.6 ± 63.9	303.9 ± 85.8
γ-GTP IU/L	1.0 ± 0.0	1.0 ± 0.0	1.0 ± 0.0	4.2 ± 0.8	1.0 ± 0.0	1.0 ± 0.0	1.0 ± 0.0	2.7 ± 0.9
CPK IU/L	406.6 ± 91.4	366.6 ± 87.9	543.2 ± 119.2	561.0 ± 199.8	357.9 ± 54.7	278.4 ± 70.3	354.2 ± 70.0	381.2 ± 97.7
CRNN mg/dL	0.3 ± 0.0	0.3 ± 0.0	0.3 ± 0.0	0.3 ± 0.0	0.3 ± 0.0	0.3 ± 0.0	0.3 ± 0.0	0.3 ± 0.0
BUN mg/dL	12.4 ± 1.1	11.8 ± 1.6	13.4 ± 0.5	12.2 ± 1.6	15.5 ± 2.3	14.5 ± 1.5	16.5 ± 2.0	15.8 ± 2.5
Glucose mg/dL	154.0 ± 26.5	144.8 ± 21.0	124.2 ± 27.2	101.8 ± 16.5**	140.3 ± 20.9	147.8 ± 17.1	124.8 ± 25.7	114.9 ± 12.2*
TG mg/dL	64.0 ± 21.7	62.6 ± 20.1	84.0 ± 38.7	43.4 ± 8.4	87.8 ± 34.8	50.9 ± 17.0**	34.9 ± 26.1**	53.3 ± 23.8*
T-Cho mg/dL	61.8 ± 6.7	64.0 ± 12.5	67.8 ± 12.0	84.0 ± 7.1**	118.0 ± 24.6	101.3 ± 13.9	105.3 ± 12.8	110.2 ± 20.6
Na mEq/L	142.0 ± 0.7	143.2 ± 1.1	142.4 ± 0.9	143.8 ± 0.4**	140.6 ± 1.2	140.9 ± 1.0	140.0 ± 1.2	141.0 ± 1.2
K mEq/L	4.7 ± 0.2	4.8 ± 0.1	4.9 ± 0.2	4.7 ± 0.0	4.5 ± 0.3	4.5 ± 0.2	4.4 ± 0.2	4.5 ± 0.2
Cl mEq/L	105.6 ± 0.9	104.8 ± 1.5	104.8 ± 1.5	104.8 ± 0.4	103.5 ± 1.7	104.8 ± 1.8	103.7 ± 1.4	103.1 ± 1.4
Ca mg/dL	9.6 ± 0.2	9.7 ± 0.2	9.8 ± 0.2	9.7 ± 0.2	10.1 ± 0.4	10.0 ± 0.4	10.3 ± 0.2	10.6 ± 0.2**
IP mg/dL	6.0 ± 0.7	6.5 ± 0.3	7.0 ± 0.4*	7.6 ± 0.2**	4.9 ± 1.2	5.1 ± 1.2	5.8 ± 0.7	6.7 ± 0.3**

\*, \*\*: Significantly different from the control group at  $p < 0.05$  and  $0.01$ , respectively.

**Table 6**  
**Final body and organ weights for SD *gpt* delta rats treated with 2-MF for 13 weeks**

Item	Male				Female			
	0 mg/kg	1.2 mg/kg	6 mg/kg	30 mg/kg	0 mg/kg	1.2 mg/kg	6 mg/kg	30 mg/kg
Body Weight	526.9±40.0	547.6±52.0	512.2±35.5	456.3±21.2**	302.9 ± 26.1	303.6±22.0	286.5±33.2	255.3±18.5**
Absolute weight (g)								
Brain	2.07±0.03	2.07±0.04	2.06±0.08	2.02±0.04	1.93 ± 0.07	1.92±0.02	1.93±0.06	1.89±0.03
Thymus	0.39±0.08	0.42±0.07	0.41±0.05	0.32±0.05*	0.33 ± 0.04	0.34±0.06	0.33±0.07	0.26±0.03**
Lungs	1.39±0.13	1.48±0.25	1.47±0.15	1.36±0.16	1.17 ± 0.25	1.09±0.11	1.07±0.12	1.03±0.10
Heart	1.43±0.13	1.38±0.14	1.38±0.12	1.24±0.10**	0.87 ± 0.06	0.86±0.06	0.82±0.06	0.78±0.06**
Spleen	0.76±0.06	0.79±0.11	0.77±0.09	0.69±0.07	0.51 ± 0.06	0.53±0.05	0.54±0.04	0.45±0.09
Liver	14.41±1.80	15.20±2.41	15.02±1.57	19.00±1.49**	7.76 ± 1.19	7.56±0.67	8.46±1.07	10.80±0.89**
Adrenals	0.05±0.01	0.05±0.00	0.06±0.01	0.06±0.01	0.06 ± 0.01	0.06±0.01	0.05±0.01	0.06±0.01
Kidneys	2.59±0.24	2.61±0.20	2.62±0.25	2.70±0.23	1.60 ± 0.15	1.60±0.19	1.53±0.15	1.70±0.15
Testes/Ovaries	3.50±0.18	3.48±0.17	3.53±0.20	3.45±0.28	0.08 ± 0.01	0.08±0.01	0.07±0.01	0.07±0.01
Relative weight (g%)								
Brain	0.39±0.03	0.38±0.04	0.40±0.03	0.44±0.02**	0.64 ± 0.06	0.64±0.05	0.68±0.07	0.74±0.05**
Thymus	0.07±0.01	0.08±0.01	0.08±0.01	0.07±0.01	0.11 ± 0.01	0.11±0.02	0.11±0.01	0.10±0.01
Lungs	0.27±0.03	0.27±0.05	0.29±0.03	0.30±0.04	0.39 ± 0.06	0.36±0.03	0.38±0.08	0.40±0.05
Heart	0.27±0.03	0.25±0.03	0.27±0.02	0.27±0.03	0.29 ± 0.02	0.29±0.02	0.29±0.02	0.31±0.02
Spleen	0.14±0.01	0.15±0.02	0.15±0.01	0.15±0.01	0.17 ± 0.01	0.17±0.02	0.19±0.02	0.18±0.03
Liver	2.73±0.21	2.76±0.23	2.93±0.14	4.16±0.23**	2.56 ± 0.32	2.49±0.18	2.96±0.21**	4.24±0.24**
Adrenals	0.01±0.00	0.01±0.00	0.01±0.00	0.01±0.00*	0.02 ± 0.00	0.02±0.00	0.02±0.00	0.02±0.00
Kidneys	0.49±0.03	0.48±0.03	0.51±0.03	0.59±0.05**	0.53 ± 0.04	0.53±0.05	0.54±0.04	0.67±0.05**
Testes/Ovaries	0.67±0.04	0.64±0.05	0.69±0.06	0.76±0.07**	0.03 ± 0.00	0.03±0.00	0.02±0.00	0.03±0.00

\*, \*\*: Significantly different from the control group at  $p < 0.05$  and  $0.01$ , respectively.

Table 7

***gpt* mutant frequencies (MFs) in the liver of SD *gpt* delta rats treated with 2-MF for 13 weeks**

Group	Male					Female				
	Animal No.	Cm <sup>R</sup> colonies (×10 <sup>5</sup> )	6-TG <sup>R</sup> and Cm <sup>R</sup> colonies	MFs (×10 <sup>-5</sup> )	Mean ± SD	Animal No.	Cm <sup>R</sup> colonies (×10 <sup>5</sup> )	6-TG <sup>R</sup> and Cm <sup>R</sup> colonies	MFs (×10 <sup>-5</sup> )	Mean ± SD
Control	1	2.2	3	1.36	0.45 ± 0.52	41	8.6	4	0.46	0.30 ± 0.13
	2	9.8	3	0.31		42	12.7	4	0.31	
	3	13.1	3	0.23		43	9.5	1	0.10	
	4	8.1	2	0.25		44	10.7	3	0.28	
	5	11.6	1	0.09		45	12.8	4	0.31	
1.2 mg/kg	11	5.9	3	0.51	0.67 ± 0.41	51	12.8	2	0.16	0.24 ± 0.25
	12	7.5	1	0.13		52	10.5	0	0.00	
	13	9.5	6	0.63		53	10.1	2	0.20	
	14	8.2	7	0.85		54	11.0	2	0.18	
	15	7.2	9	1.24		55	12.2	8	0.66	
6 mg/kg	21	8.3	2	0.24	0.63 ± 0.34	61	12.0	5	0.42	0.58 ± 0.51
	22	1.4	3	2.08 <sup>a</sup>		62	9.1	5	0.55	
	23	7.8	7	0.89		63	5.9	1	0.17	
	24	0.2	0	0.00 <sup>a</sup>		64	7.4	1	0.13	
	25	5.4	4	0.75		65	7.8	9	1.15	
30 mg/kg	31	2.7	0	0.00	0.36 ± 0.39	71	8.6	2	0.23	1.09 ± 1.24
	32	6.5	1	0.15		72	3.3	2	0.60	
	33	7.5	3	0.40		73	4.1	2	0.48	
	34	8.7	2	0.23		74	7.2	22	3.06	
	35	3.0	3	1.01		75	1.8	0	0.00 <sup>a</sup>	
ENU 50 mg/kg (positive control)	P	17.1	180	10.55		P	15.2	174	11.47	

<sup>a</sup>: The data of animal No. 22, 24 and 75 were excluded from calculation because of poor packaging efficiencies.

**Table 8****Spi<sup>-</sup> mutant frequencies (MFs) in the liver of SD *gpt* delta rats treated with 2-MF for 13 weeks**

Group	Male					Female				
	Animal No.	Plaques within XL-1 Blue MRA ( $\times 10^5$ )	Plaques within WL95 (P2)	MFs ( $\times 10^{-5}$ )	Mean $\pm$ SD	Animal No.	Plaques within XL-1 Blue MRA ( $\times 10^5$ )	Plaques within WL95 (P2)	MFs ( $\times 10^{-5}$ )	Mean $\pm$ SD
Control	1	10.3	3	0.29	0.32 $\pm$ 0.11	41	14.5	4	0.28	0.25 $\pm$ 0.05
	2	15.8	3	0.19		42	9.1	3	0.33	
	3	17.6	6	0.34		43	13.6	3	0.22	
	4	13.1	4	0.30		44	14.2	3	0.21	
	5	14.5	7	0.48		45	14.7	3	0.20	
1.2 mg/kg	11	12.1	5	0.41	0.26 $\pm$ 0.112	51	9.7	4	0.41	0.30 $\pm$ 0.13
	12	10.2	2	0.20		52	13.7	5	0.37	
	13	12.2	4	0.33		53	8.6	2	0.23	
	14	12.2	3	0.25		54	10.7	4	0.37	
	15	11.2	1	0.09		55	10.4	1	0.10	
6 mg/kg	21	12.5	3	0.24	0.21 $\pm$ 0.05	61	8.1	3	0.37	0.30 $\pm$ 0.08
	22	5.4	1	0.19		62	8.6	2	0.23	
	23	12.1	3	0.25		63	8.2	2	0.24	
	24	1.7	0	0.00 <sup>a</sup>		64	12.0	3	0.25	
	25	6.8	1	0.15		65	7.7	3	0.39	
30 mg/kg	31	5.0	1	0.20	0.37 $\pm$ 0.22	71	10.1	3	0.30	0.26 $\pm$ 0.09
	32	5.2	2	0.38		72	9.1	1	0.11	
	33	10.6	6	0.56		73	8.7	3	0.34	
	34	10.2	1	0.10		74	9.8	3	0.31	
	35	3.2	2	0.62		75	8.0	2	0.25	
ENU 50 mg/kg (positive control)	P	25.6	44	1.72		P	12.7	33	2.60	

<sup>a</sup>: The data of animal No. 24 were excluded from calculation because of poor packaging efficiencies.

### Ⅲ. 研究成果の刊行に関する一覧表



## 別紙 4

## 研究成果の刊行に関する一覧表レイアウト

## 書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書 籍 名	出版社名	出版地	出版年	ページ
	該当なし						

## 雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Matsushita K, Kijima A, Ishii Y, Takasu S, Jin M, Kuroda K, Kawaguchi H, Miyoshi N, Nohmi T, <u>Ogawa K</u> , <u>Umemura T</u>	Development of a medium-term animal model using <i>gpt</i> delta rats to evaluate chemical carcinogenicity and genotoxicity	<i>J. Toxicol. Pathol.</i> .	26	19-27	2013
Jin M, Kijima A, Hibi D, Ishii Y, Takasu S, Matsushita K, Kuroda K, Nohmi T, <u>Nishikawa A</u> , <u>Umemura T</u>	<i>In vivo</i> genotoxicity of methyleugenol in <i>gpt</i> delta transgenic rats following medium-term exposure	Toxicol Sci.	131	387-394	2013
Jin M, Kijima A, Suzuki Y, Hibi D, Ishii Y, Nohmi T, <u>Nishikawa A</u> , <u>Ogawa K</u> , <u>Umemura T</u>	<i>In vivo</i> genotoxicity of 1-methylnaphthalene from comprehensive toxicity studies with B6 C3F <sub>1</sub> <i>gpt</i> delta mice	J. Toxicol. Sci.	37	711-721	2013

#### IV. 研究成果の刊行物・別刷り

Original Article

## Development of a Medium-term Animal Model Using *gpt* Delta Rats to Evaluate Chemical Carcinogenicity and Genotoxicity

Kohei Matsushita<sup>1</sup>, Aki Kijima<sup>1</sup>, Yuji Ishii<sup>1</sup>, Shinji Takasu<sup>1</sup>, Meilan Jin<sup>1</sup>, Ken Kuroda<sup>1</sup>, Hiroaki Kawaguchi<sup>2</sup>, Noriaki Miyoshi<sup>2</sup>, Takehiko Nohmi<sup>3</sup>, Kumiko Ogawa<sup>1</sup>, and Takashi Umemura<sup>1\*</sup>

<sup>1</sup> Division of Pathology, National Institute of Health Sciences, 1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan

<sup>2</sup> Laboratory of Veterinary Histopathology, Joint Faculty of Veterinary Medicine, Kagoshima University, 1-21-24 Korimoto, Kagoshima 890-8508, Japan

<sup>3</sup> Biological Safety Research Center, National Institute of Health Sciences, 1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan

**Abstract:** In this study, the potential for development of an animal model (GPG46) capable of rapidly detecting chemical carcinogenicity and the underlying mechanisms of action were examined in *gpt* delta rats using a reporter gene assay to detect mutations and a medium-term rat liver bioassay to detect tumor promotion. The tentative protocol for the GPG46 model was developed based on the results of dose-response exposure to diethylnitrosamine (DEN) and treatment with phenobarbital over time following DEN administration. Briefly, *gpt* delta rats were exposed to various chemicals for 4 weeks, followed by a partial hepatectomy (PH) to collect samples for an *in vivo* mutation assay. The mutant frequencies (MFs) of the reporter genes were examined as an indication of tumor initiation. A single intraperitoneal (ip) injection of 10 mg/kg DEN was administered to rats 18 h after the PH to initiate hepatocytes. Tumor-promoting activity was evaluated based on the development of glutathione S-transferase placental form (GST-P)-positive foci at week 10. The genotoxic carcinogens 2-acetylaminofluorene (2-AAF), 2-amino-3-methylimidazo [4,5-f] quinolone (IQ) and safrole (SF), the non-genotoxic carcinogens piperonyl butoxide (PBO) and phenytoin (PHE), the non-carcinogen acetaminophen (APAP) and the genotoxic non-hepatocarcinogen aristolochic acid (AA) were tested to validate the GPG46 model. The validation results indicate that the GPG46 model could be a powerful tool in understanding chemical carcinogenesis and provide valuable information regarding human risk hazards. (DOI: 10.1293/tox.26.19; J Toxicol Pathol 2013; 26: 19–27)

**Key words:** medium-term animal model, carcinogenicity, *gpt* delta rats, *in vivo* genotoxicity, glutathione S-transferase placental form

### Introduction

Environmental chemicals, including pharmaceuticals, agrochemicals and food additives, are important in various aspects of daily life. However, these chemicals may pose a risk to humans, and their toxicities have been extensively assessed in animal studies. In particular, carcinogenicity is a key component of safety assessments because the resulting lesions can be irreversible and are often fatal. The current gold standard for assessing the risk of cancer is a lifetime bioassay in rodents, but this method requires over 3 years to complete, including histopathological procedures<sup>1</sup>. It is estimated that only approximately 1500 chemicals have been tested over the past 30 years despite the addition of nearly 4000 new chemicals in the Chemical Abstracts Ser-

vice (CAS) Registry database every day<sup>2,3</sup>. Although conventional lifetime bioassays can provide data regarding the potential carcinogenicity and target organs of various chemicals, these assays do not provide any information about the associated mechanisms of action that influence carcinogenesis. The development of bioassays that can rapidly detect chemical carcinogenicity and provide information about the underlying mechanisms of action is currently being pursued.

Thresholds in dose-related chemical carcinogenicity curves depend on the involvement of genotoxic mechanisms<sup>4</sup>. Mutagenicity and carcinogenicity are important factors when determining risk assessments<sup>5</sup>. Although *in vitro* genotoxic assays, such as the Ames test, the micronucleus test and the chromosomal aberration test, are considered standard tools for investigating chemical mutagenicity, the results of these methods are not necessarily indicative of carcinogenicity<sup>5</sup>. Reporter gene mutation assays are promising genotoxic techniques because *in vivo* metabolic processes can be evaluated at the target organs<sup>6</sup>. Comprehensive toxicity studies and the measurement of DNA adducts, oxidative stress and enzymatic activities have been demon-

Received: 13 September 2012, Accepted: 6 November 2012

\*Corresponding author: T Umemura (e-mail: umemura@nihs.go.jp)

©2013 The Japanese Society of Toxicologic Pathology

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License <<http://creativecommons.org/licenses/by-nc-nd/3.0/>>.

strated in animal models using *gpt* delta rodents<sup>7-10</sup>. Using the reliable preneoplastic marker glutathione S-transferase placental form (GST-P) foci, medium-term rat liver bioassays have been developed to rapidly detect tumor promoters because the liver is the most common target organ for carcinogenesis<sup>11</sup>. However, the conventional medium-term bioassays do not provide information regarding the involvement of genotoxic mechanisms in carcinogenesis as a result of exposure to test compounds.

In this study, we evaluated the possibility of developing a new animal model designed to rapidly detect chemical carcinogenicity and underlying molecular mechanisms using a reporter gene mutation assay and a medium-term liver bioassay. The conditions were optimized to establish a tentative experimental protocol, and validation of the model was confirmed using several carcinogens.

## Materials and Methods

### Chemicals

Diethylnitrosamine (DEN) and safrole (SF) were purchased from Tokyo Kasei Kogyo (Tokyo, Japan). Phenobarbital (PhB), 2-acetylaminofluorene (2-AAF), piperonyl-butoxide (PBO), and phenytoin (PHE) were obtained from Wako Pure Chemical Industries (Osaka, Japan), and acetaminophen (APAP) was purchased from MP Biomedicals (Irvine, CA, USA). 2-Amino-3-methylimidazo [4,5-f] quinolone (IQ) and aristolochic acid (AA) were obtained from Toronto Research Chemicals (North York, ON, Canada) and Sigma-Aldrich (St. Louis, MO, USA), respectively.

### Experimental animals and housing conditions

The protocol was approved by the Animal Care and Utilization Committee of the National Institute of Health Sciences. Five- or nine-week-old specific pathogen-free F344/NSlc rats or five-week-old specific pathogen-free F344/NSlc-Tg (*gpt* delta) rats carrying approximately five tandem copies of the transgene lambda EG10 per haploid genome were obtained from Japan SLC (Shizuoka, Japan) and acclimated for 1 week prior to testing. The rats were housed in polycarbonate cages (two or three rats per cage) with hardwood chips for bedding in a conventional animal facility. Animals were maintained under controlled temperature ( $23 \pm 2^\circ\text{C}$ ), relative humidity ( $55 \pm 5\%$ ), air changes (12 times/h), and lighting (12 h light-dark cycle) conditions with free access to a basal diet (CRF-1; Oriental Yeast Co., Ltd, Tokyo, Japan) and tap water. At the end of each experiment, the rats were euthanized by exsanguination via transection of the abdominal aorta under deep anesthesia.

### Animal treatments

Experiment I: The effects of a single administration of DEN on the development of GST-P-positive foci were evaluated. A partial hepatectomy (PH) was performed on ten-week-old male F344/NSlc rats ( $n=5$  rats per dose). After 18 h, an intraperitoneal (ip) injection of DEN was administered at doses of 0, 10, 50, and 100 mg/kg. Six weeks after the

start of the experiment, the rat livers were fixed in 10% neutral-buffered formalin. The fixed tissues were embedded in paraffin, sectioned and evaluated using immunohistochemistry for the quantitative analysis of GST-P-positive foci.

Experiment II: Changes in the development of GST-P-positive foci over time following administration of PhB after a PH and single dose exposure to DEN were examined. Six-week-old male F344/NSlc rats ( $n=10$  rats per dose) were fed PhB at concentrations of 0 and 500 ppm in their basal diets. This dose was selected based on a previous carcinogenicity test<sup>12</sup>. After 4 weeks, a PH was performed. An ip injection of DEN at a dose of 10 mg/kg was administered 18 h after the PH. The rats continued to feed on a diet containing PhB until they were sacrificed at 10, 12, or 14 weeks after the start of the experiment. The livers were fixed in 10% neutral-buffered formalin, and the tissues were embedded in paraffin, sectioned and evaluated using immunohistochemistry for the quantitative analysis of GST-P-positive foci.

Experiment III: Validation of the animal model was confirmed using genotoxic, non-genotoxic carcinogens and a non-carcinogen. Six-week-old male F344/NSlc-Tg (*gpt* delta) rats ( $n=15$  per dose) were fed 20 ppm 2-AAF, 12000 ppm PBO or 6000 ppm APAP in their basal diets. A control group was fed the basal diet without chemical supplementation. The 2-AAF dose was selected based on a preliminary study in which no toxic effects were observed in rats treated with 20 ppm (data not shown). The doses of PBO and APAP were selected based on previous carcinogenicity tests<sup>13,14</sup>. The animal model was further validated using genotoxic and non-genotoxic carcinogens and a genotoxic non-hepatocarcinogen. Six-week-old male F344/NSlc-Tg (*gpt* delta) rats ( $n=15$  per dose) were fed 20 ppm IQ, 5000 ppm SF or 2400 ppm PHE in their basal diets. The rats treated with AA received 0.3 mg/kg body weight in 1% sodium bicarbonate by gavage once a day. A control group was fed the basal diet without chemical supplementation. The IQ dose was selected based on a preliminary study in which no toxic effects were observed in rats treated with 20 ppm (data not shown). The doses of SF and PHE were selected based on previous carcinogenicity tests<sup>15,16</sup>, and the dose of AA was determined based on a previous report in which the *gpt* mutant frequencies (MFs) were increased in rats treated with AA for 4 weeks<sup>17</sup>. The carcinogenic properties of the test chemicals are summarized in Table 1. A PH was performed on all rats after 4 weeks, and an ip injection of DEN at a dose of 10 mg/kg was administered 18 h after the PH. The excised liver tissues were perfused with saline to remove residual blood and stored at  $-80^\circ\text{C}$  for the *gpt* assay. The rats continued to feed on the basal diets containing the various chemicals. Ten weeks after the start of the experiment, the livers were fixed in 10% neutral-buffered formalin. The fixed tissues were embedded in paraffin, sectioned and evaluated using immunohistochemistry for the quantitative analysis of GST-P-positive foci.

**Table 1.** Summary of the carcinogenic properties of the test chemicals used in the validation study

Test chemical	Mutagenicity	Carcinogenicity	Principal site of tumor induction	Group
2-AAF	+	+	Liver, Bladder, Zymbal gland	Genotoxic carcinogen
IQ	+	+	Liver, Forestomach, Intestines	
SF	+	+	Liver	
PBO	–	+	Liver	Non-genotoxic carcinogen
PHE	–	±*	Liver	
AA	+	+	Kidney, Urinary tract, Forestomach	Genotoxic non-hepatocarcinogen
APAP	–	–	–	Non-carcinogen

\* The carcinogenic activity of PHE is classified as “equivocal evidence” based on studies that have shown a marginal increase in neoplasms that may be related to chemical exposure in a NTP technical report<sup>16</sup>.

### *In vivo* mutation assays

6-Thioguanine (6-TG) was used according to the method described in Nohmi *et al.*<sup>18</sup>. Briefly, genomic DNA was extracted from each liver, and the lambda EG10 DNA (48 kb) was rescued in phages by *in vitro* packaging. For 6-TG selection, the packaged phages were incubated with *Escherichia coli* YG6020, which expresses Cre recombinase, and converted to plasmids carrying genes encoding *gpt* and chloramphenicol acetyltransferase. The infected cells were mixed with molten soft agar and poured onto agar plates containing chloramphenicol and 6-TG. To determine the total number of rescued plasmids, the infected cells were poured on plates containing chloramphenicol without 6-TG. The plates were incubated at 37°C for the selection of 6-TG-resistant colonies. Positive colonies were counted on day 3 and collected on day 4. The *gpt* MFs were calculated by dividing the number of *gpt* mutants by the number of rescued phages.

### Immunohistochemical staining for GST-P

Immunohistochemical staining was performed using polyclonal antibodies against GST-P (1:1000 dilution; Medical & Biological Laboratories Co., Ltd., Nagoya, Japan). The number and area of GST-P-positive foci consisting of 5 or more nucleated hepatocytes in a crosssection were evaluated using an image analyzer (IPAP, Sumika Technoservice, Hyogo, Japan)<sup>19</sup>.

### Statistics

The number and area of GST-P-positive foci in experiment I were analyzed using ANOVA followed by Dunnett's multiple comparison test. The number and area of GST-P-positive foci in experiments II, III and IV and the *gpt* MFs in experiments III and IV were analyzed by assessing the variance for homogeneity using the *F*-test. The Student's *t*-test and Welch's *t*-test were used for homogeneous and heterogeneous data, respectively. The *gpt* MFs in the rats treated with SF in experiment IV were analyzed using the Mann-Whitney U test.

## Results

### Experiment I

Two of the rats in the control group died due to surgical complications of the PH and were eliminated from further evaluation. Treatment with DEN increased the number and area of GST-P-positive foci in a dose-dependent manner compared with the control group (Table 2), although the differences were not significant in the rats that were treated with 10 mg/kg and 50 mg/kg.

### Experiment II

Two rats from the 14-week control group, one rat from the 10-week PhB group and one rat from the 12-week PhB group died due to surgical complications of the PH and were eliminated from further evaluation. The number and area of GST-P-positive foci were significantly increased in the rats treated with PhB in each experimental time period (Table 2).

### Experiment III

Three rats in the control group, one rat in the group treated with 2-AAF, five rats in the group treated with PBO and one rat in the group treated with APAP died due to surgical complications of the PH and were eliminated from further evaluation. Table 3 shows the MFs in the excised livers of *gpt* delta rats that were treated with 2-AAF, PBO or APAP for 4 weeks. The MFs in the rats treated with 2-AAF were significantly increased compared with the rats in the control group. No significant changes were observed in the rats treated with PBO or APAP. In the *gpt* mutation spectra, GC:TA and GC:CG transversions and single base pair deletions were significantly increased in the rats treated with 2-AAF (Table 4). The number and area of GST-P-positive foci were significantly increased in livers of the rats treated with 2-AAF or PBO and significantly decreased in the livers of the rats treated with APAP (Table 2).

One rat in the control group, four rats in the group treated with IQ, eight rats in the group treated with SF, three rats in the group treated with PHE and two rats in the group treated with AA died due to surgical complications of the PH and were eliminated from further evaluation. Table 5 shows the MFs in the excised livers of *gpt* delta rats that were treated with IQ, SF, PHE or AA for 4 weeks. The MFs in the rats treated with IQ, SF and AA were significantly

**Table 2.** Quantitative analysis of GST-P-positive foci

Groups	No. of rats	No. of foci (No./cm <sup>2</sup> )	Area of foci (mm <sup>2</sup> /cm <sup>2</sup> )
Experiment I			
Control	3	0.21 ± 0.36	0.002 ± 0.003
DEN 10 mg/kg	5	7.65 ± 3.42	0.072 ± 0.034
DEN 50 mg/kg	5	20.06 ± 3.60	0.326 ± 0.103
DEN 100 mg/kg	5	28.31 ± 5.78**	1.042 ± 0.297**
Experiment II			
10 weeks			
Control	10	5.72 ± 2.47	0.038 ± 0.019
PhB	9	19.81 ± 4.08**	0.153 ± 0.035**
12 weeks			
Control	10	8.59 ± 4.33	0.053 ± 0.028
PhB	9	22.36 ± 4.89**	0.171 ± 0.043**
14 weeks			
Control	8	7.39 ± 2.60	0.053 ± 0.019
PhB	10	26.53 ± 4.41**	0.243 ± 0.048**
Experiment III			
Control	12	4.70 ± 1.53	0.027 ± 0.011
2-AAF	14	24.79 ± 6.15**	0.630 ± 0.315**
PBO	10	7.94 ± 2.22**	0.054 ± 0.015**
APAP	14	0.98 ± 0.42**	0.005 ± 0.002**
Control	14	4.40 ± 1.59	0.025 ± 0.010
IQ	11	7.83 ± 3.33**	0.046 ± 0.019**
SF	7	37.02 ± 10.03**	0.586 ± 0.293**
PHE	12	17.29 ± 5.55**	0.113 ± 0.040**
AA	13	4.70 ± 1.86	0.029 ± 0.015

\*\*Significantly different from the control group at  $p < 0.01$ .

**Table 3.** *gpt* MFs in livers of F344 *gpt* delta rats treated with 2-AAF, PBO and APAP

Group	Animal no.	Cm <sup>R</sup> colonies (× 10 <sup>5</sup> )	6-TG <sup>R</sup> and Cm <sup>R</sup> Colonies	MF (× 10 <sup>-5</sup> )	Mean ± SD
Control	101	11.75	5	0.43	0.44 ± 0.10
	102	22.46	6	0.27	
	103	11.07	6	0.54	
	104	8.46	4	0.47	
	105	10.62	5	0.47	
2-AAF	201	8.33	12	1.44	2.07 ± 0.85**
	202	12.20	14	1.15	
	203	7.79	15	1.93	
	204	8.15	21	2.58	
	205	8.96	29	3.24	
PBO	301	7.70	1	0.13	0.49 ± 0.27
	302	8.42	7	0.83	
	303	7.65	5	0.65	
	304	15.03	5	0.33	
	305	8.10	4	0.49	
APAP	401	18.77	4	0.21	0.40 ± 0.14
	402	18.68	7	0.37	
	403	11.39	7	0.61	
	404	15.53	6	0.39	
	405	14.45	6	0.42	

\*\*Significantly different from the control group at  $p < 0.01$ .

increased compared with the rats in the control group. In the *gpt* mutation spectra, GC:TA transversions, GC:AT transversions and single base pair deletions were significantly increased in the rats treated with IQ, and AT:TA transversions

were significantly increased in the rats treated with AA (Table 6). No significant changes were observed in the rats treated with SF. The number and area of GST-P-positive foci were significantly increased in the livers of the rats treated

**Table 4.** Mutation spectra of *gpt* mutant colonies in livers of F344 *gpt* delta rats treated with 2-AAF, PBO and APAP

	Control		2-AAF		PBO		APAP	
	Number (%)	Mutation frequency ( $10^{-5}$ )	Number (%)	Mutation frequency ( $10^{-5}$ )	Number (%)	Mutation frequency ( $10^{-5}$ )	Number (%)	Mutation frequency ( $10^{-5}$ )
<b>Transversions</b>								
GC-TA	6 <sup>a</sup> (23.1)	0.11 ± 0.08	32 (35.2)	0.72 ± 0.27**	5 (22.7)	0.13 ± 0.16	7 (23.3)	0.01 ± 0.09
GC-CG	1 (3.8)	0.01 ± 0.02	9 (9.9)	0.20 ± 0.17*	1 (4.5)	0.02 ± 0.05	3 (10.0)	0.03 ± 0.05
AT-TA	1 (3.8)	0.02 ± 0.04	8 (8.8)	0.17 ± 0.21	2 (9.1)	0.03 ± 0.06	3 (10.0)	0.04 ± 0.05
AT-CG	1 (3.8)	0.11 ± 0.02	3 (3.3)	0.07 ± 0.15	1 (4.5)	0.02 ± 0.06	1 (3.3)	0.02 ± 0.04
<b>Transitions</b>								
GC-AT	15 (57.7)	0.26 ± 0.08	19 (20.9)	0.39 ± 0.35	9 (40.9)	0.20 ± 0.14	14 (46.7)	0.19 ± 0.09
AT-GC	0	0	4 (4.4)	0.10 ± 0.11	1 (4.5)	0.02 ± 0.05	0	0
<b>Deletion</b>								
Single bp	1 (3.8)	0.02 ± 0.04	12 (13.2)	0.28 ± 0.21*	2 (9.1)	0.04 ± 0.06	2 (6.7)	0.03 ± 0.04
Over 2 bp	0	0	1 (1.1)	0.02 ± 0.05	1 (4.5)	0.02 ± 0.05	0	0
<b>Insertion</b>								
Complex	1 (3.8)	0.02 ± 0.04	3 (3.3)	0.07 ± 0.07	0	0	0	0
Complex	0	0	0	0	0	0	0	0

<sup>a</sup> Number of colonies with independent mutations.\*\*\*Significantly different from the control group at  $p < 0.05$  and  $p < 0.01$ , respectively.

**Table 5.** *gpt* MFs in livers of F344 *gpt* delta rats treated with IQ, SF, PHE and AA

Group	Animal no.	Cm <sup>R</sup> colonies ( $\times 10^5$ )	6-TG <sup>R</sup> and Cm <sup>R</sup> colonies	MF ( $\times 10^{-5}$ )	Mean ± SD
Control	101	15.1	3	0.20	0.38 ± 0.19
	102	6.8	4	0.59	
	103	15.9	7	0.44	
	104	12.2	2	0.16	
	105	8.1	4	0.50	
IQ	201	8.9	18	2.03	3.35 ± 1.22**
	202	7.2	34	4.69	
	203	6.1	18	2.94	
	204	10.4	26	2.49	
	205	4.4	20	4.58	
SF	301	10.0	8	0.80	1.18 ± 0.74**
	302	5.0	5	1.00	
	303	5.6	14	2.49	
	304	10.1	7	0.69	
	305	5.4	5	0.92	
PHE	401	7.9	3	0.38	0.36 ± 0.26
	402	4.5	1	0.22	
	403	11.4	1	0.09	
	404	5.9	2	0.34	
	405	7.7	6	0.78	
AA	501	8.6	13	1.50	1.18 ± 0.41**
	502	9.8	17	1.73	
	503	12.9	12	0.93	
	504	11.3	9	0.79	
	505	9.5	9	0.95	

\*\*Significantly different from the control group at  $p < 0.01$ .

with IQ, SF and PHE (Table 2).

## Discussion

Chemical carcinogenesis involves multiple gene alterations, which can be divided into initiation and promotion phases. A medium-term rat liver bioassay involving the quantitative analysis of GST-P-positive foci following cell proliferative stimuli via PH was established to detect the

tumor promoting activities of various chemicals. Reporter gene mutation assays using transgenic animals have been developed to detect *in vivo* mutagenicity. Because this assay can be performed under conditions that are similar to the conventional long-term bioassay, the results may represent the tumor initiation phase of chemical carcinogenesis. GST-P-positive foci have been analyzed in *gpt*delta rats<sup>7,20,21</sup>. The GPG46 animal model described in this study can detect the tumor-initiating and tumor-promoting activities of vari-


**Table 6.** Mutation spectra of *gpt* mutant colonies in livers of F344 *gpt* delta rats treated with IQ, SF, PHE and AA

	Control		IQ		SF		PHE		AA	
	Number (%)	Mutation frequency ( $10^{-5}$ )	Number (%)	Mutation frequency ( $10^{-5}$ )	Number (%)	Mutation frequency ( $10^{-5}$ )	Number (%)	Mutation frequency ( $10^{-5}$ )	Number (%)	Mutation frequency ( $10^{-5}$ )
<b>Transversions</b>										
GC-TA	5 <sup>a</sup> (25.0)	0.11 ± 0.09	50 (43.1)	1.40 ± 0.41**	13 (33.3)	0.41 ± 0.38	4 (30.8)	0.10 ± 0.17	11 (18.3)	0.21 ± 0.09
GC-CG	1 (5.0)	0.01 ± 0.03	4 (3.5)	0.11 ± 0.25	6 (15.4)	0.17 ± 0.13	1 (7.7)	0.03 ± 0.06	1 (1.7)	0.02 ± 0.05
AT-TA	0	0	6 (5.2)	0.20 ± 0.18	3 (7.7)	0.09 ± 0.09	0	0	29 (48.3)	0.55 ± 0.30
AT-CG	0	0	1 (0.9)	0.03 ± 0.06	2 (5.1)	0.06 ± 0.08	0	0	0	0
<b>Transitions</b>										
GC-AT	8 (40.0)	0.14 ± 0.11	14 (12.1)	0.40 ± 0.16*	6 (15.4)	0.17 ± 0.14	6 (46.2)	0.16 ± 0.15	7 (11.7)	0.15 ± 0.13
AT-GC	3 (15.0)	0.07 ± 0.13	0	0	4 (10.3)	0.13 ± 0.15	1 (7.7)	0.03 ± 0.08	2 (3.3)	0.04 ± 0.09
<b>Deletion</b>										
Single bp	3 (15.0)	0.04 ± 0.04	39 (33.6)	1.17 ± 0.58*	3 (7.7)	0.10 ± 0.17	1 (7.7)	0.03 ± 0.08	8 (13.3)	0.16 ± 0.16
Over 2 bp	0	0	1 (0.9)	0.02 ± 0.04	0	0	0	0	0	0
Insertion	0	0	1 (0.9)	0.02 ± 0.05	2 (5.1)	0.06 ± 0.08	0	0	2 (3.3)	0.04 ± 0.06
Complex	0	0	0	0	0	0	0	0	0	0

<sup>a</sup> Number of colonies with independent mutations. \*\*\*Significantly different from the control group at  $p < 0.05$  and  $p < 0.01$ , respectively.

ous chemicals by combining the reporter gene mutation assay and the medium-term liver bioassay.

In this animal model, *gpt* delta rats were exposed to chemicals, and a PH was performed to collect liver samples for an *in vivo* mutation assay. The rats were subsequently administered a single ip injection of DEN, and the tumor promoting activity of the chemical was evaluated based on the development of GST-P-positive foci. The World Health Organization (WHO) guidelines state that 4 weeks of exposure is sufficient for detecting mutations in the reporter gene<sup>6</sup>, which is supported by additional data<sup>8,22</sup>. Therefore, the period of exposure prior to PH in this study was determined to be 4 weeks. Initial exposure to a potent genotoxic carcinogen is necessary to detect tumor promoting activities over a short period of time. In this model, DEN was selected because correlations between the administration of DEN and the induction of GST-P foci in the rat liver have been extensively reported<sup>23-26</sup>. However, the dose of DEN should be as low as possible to avoid any effects on the metabolism of the test chemical because DEN has been shown to influence various parameters, including the induction of cytochrome P450 (CYP) and glutathione S-transferase<sup>27,28</sup>. We took advantage of the rapid induction of cell proliferation following PH because genotoxic compounds can effectively induce gene mutations under conditions of high cell proliferation<sup>4</sup>. Tsuda *et al.*<sup>29</sup> reported that the initiator should optimally be administered 18 h after PH to effectively enhance initiation. Based on these data, appropriate dosages of DEN were investigated in a dose-response study consisting of single ip injections of DEN 18 h after PH at doses of 10 mg/kg and higher. The optimal dosage of DEN was established as 10 mg/kg based on the quantitative analysis of GST-P-positive foci. PhB, a liver tumor promoter in rodents<sup>30</sup>, was used to determine the optimal duration of exposure following a PH in experiment II. The results of this study demonstrate that treatment with PhB at 500 ppm in the diet for 6 weeks is



**Fig. 1.** Tentative protocol for the GPG46 model. Six-week-old male F344 *gpt* delta rats were exposed to various chemicals for 10 weeks. A partial hepatectomy (PH) was performed at week 4, and the rats were administered a single ip injection of 10 mg/kg diethylnitrosamine (DEN) 18 h after PH. The *gpt* assay, which is an indicator of tumor initiation, was performed using the liver samples excised via PH at week 4. Tumor promoting activities were evaluated based on the development of GST-P-positive foci induced by DEN at week 10.

effective in detecting the effects of tumor promotion. The tentative protocol for the GPG46 animal model is shown in Fig. 1.

The animal model was validated in experiment III. 2-AAF, IQ and SF are genotoxic murine liver carcinogens that produce deoxyguanine adducts via metabolic activation and play a key role in liver carcinogenesis<sup>31-34</sup>. A significant increase in the MFs of the *gpt* genes in the rats treated with 2-AAF, IQ and SF was shown using the GPG46 model. Spectrum analysis in the *gpt* mutant colonies revealed that guanine-related mutations and single base pair deletions were induced by 2-AAF and IQ, but not SF, which is in agreement with previous reports<sup>35-37</sup>. In the conventional medium-term bioassay, 2-AAF, IQ and SF exposure induced a marked in-



crease in the development of GST-P-positive foci<sup>38</sup>, implying that these chemicals also exert a strong tumor promoting action. The GPG46 animal model showed that the development of GST-P-positive foci at 10 weeks was markedly increased in the livers of rats treated with these carcinogens. PBO and PHE were reported to act as hepatocarcinogens in F344 rats fed a diet containing 12000 ppm and 2400 ppm for 2 years, respectively<sup>13,16</sup>. These compounds are classified as non-genotoxic carcinogens based on the results of various-genotoxicity studies<sup>16,39</sup>. An increase in the development of GST-P-positive foci was observed in rats treated with PBO or PHE in a conventional medium-term bioassay<sup>38,40</sup>. Treatment with PBO and PHE at the carcinogenic dose in the GPG46 animal model did not increase the *gpt* MF, although the development of GST-P-positive foci was significantly increased. APAP was not reported to be hepatocarcinogenic in F344 rats fed a diet containing 6000 ppm for 2 years<sup>14</sup>. In the present study, treatment with APAP in the GPG46 model at a dose of 6000 ppm did not increase the *gpt* MF and inhibited the development of GST-P-positive foci. Ito *et al.*<sup>38</sup> showed that APAP had an inhibitory effect on the development of GST-P-positive foci in a conventional medium-term bioassay. AA has been reported to be carcinogenic in the kidney and the stomach of rodents<sup>41</sup>. In an *in vivo* genotoxicity study in Big Blue transgenic rats, AA exposure elevated *cII* MFs and produced AA-specific deoxyadenine and deoxyguanine adducts in the kidney and the liver<sup>42</sup>. A significant increase in *gpt* MFs in rats treated with AA was observed in the GPG46 model, and AT:TA transversions were the predominant mutation in the mutation spectra analysis, which is similar to a previous report<sup>42</sup>. AA did not have an enhancing effect on the development of GST-P-positive foci, which may reflect the fact that AA exerts initiation activity, but not carcinogenicity, in the liver.

Overall, the validation results show the possibility of developing a new animal model using *gpt* delta rats. However, a possible limitation of the tentative protocol is that the test chemicals are co-administered simultaneously with DEN. Although there did not appear to be any mutual effects between DEN and the test chemicals, this treatment regimen may modify the detoxification or metabolic activation of DEN. Several isoforms of CYP have been reported to participate in the metabolic activation of DEN, with CYP2E1 in particular playing an essential role<sup>43</sup>. Because many liver tumor promoters in rodents can induce several types of CYPs and/or modify the expression of phase II enzymes, we are working toward improving the timing of the regimen to avoid the possibility of mutual effects. Validation studies of the revised protocol based on changes in the timing of chemical administration are currently in progress.

In conclusion, the potential development of a GPG46 medium-term animal model to evaluate the tumor-initiating and tumor-promoting activities of various chemicals in a single study was demonstrated. In this assay, additional analyses, such as quantification of DNA modifications, the activities of metabolic enzymes and the mRNA levels of tumor-associated genes, are valuable for understanding the

modes of action of various test chemicals.

**Acknowledgments:** We appreciate the expert technical assistance of Ms. Ayako Kaneko and Ms. Yoshimi Komatsu. This work was supported by a Grant-in-Aid for Research on Food Sanitation from the Ministry of Health, Labour and Welfare of Japan (H-24-shokuhin-ippan-012).

## References

1. Paules RS, Aubrecht J, Corvi R, Garthoff B, and Kleinjans JC. Moving forward in human cancer risk assessment. *Environ Health Perspect.* **119**: 739–743. 2011.
2. Binetti R, Costamagna FM, and Marcello I. Exponential growth of new chemicals and evolution of information relevant to risk control. *Ann Ist Super Sanita.* **44**: 13–15. 2008.
3. Mahadevan B, Snyder RD, Waters MD, Benz RD, Kemper RA, Tice RR, and Richard AM. Genetic toxicology in the 21st century: reflections and future directions. *Environ Mol Mutagen.* **52**: 339–354. 2011.
4. Cohen SM, and Arnold LL. Chemical carcinogenesis. *Toxicol Sci.* **120** (Suppl 1): S76–S92. 2011.
5. Kirkland D, and Speit G. Evaluation of the ability of a battery of three *in vitro* genotoxicity tests to discriminate rodent carcinogens and non-carcinogens III. Appropriate follow-up testing *in vivo*. *Mutat Res Genet Toxicol Environ Mutagen.* **654**: 114–132. 2008.
6. World Health Organization (WHO) Transgenic Animal Mutagenicity Assays. *Environmental Health Criteria*, Vol 233. Geneva, Switzerland. 2006.
7. Jin M, Kijima A, Suzuki Y, Hibi D, Inoue T, Ishii Y, Nohmi T, Nishikawa A, Ogawa K, and Umemura T. Comprehensive toxicity study of safrole using a medium-term animal model with *gpt* delta rats. *Toxicology.* **290**: 312–321. 2011.
8. Suzuki Y, Umemura T, Hibi D, Inoue T, Jin M, Ishii Y, Sakai H, Nohmi T, Yanai T, Nishikawa A, and Ogawa K. Possible involvement of genotoxic mechanisms in estragole-induced hepatocarcinogenesis in rats. *Arch Toxicol.* **86**: 1593–1601. 2012.
9. Tasaki M, Umemura T, Suzuki Y, Hibi D, Inoue T, Okamura T, Ishii Y, Maruyama S, Nohmi T, and Nishikawa A. Oxidative DNA damage and reporter gene mutation in the livers of *gpt* delta rats given non-genotoxic hepatocarcinogens with cytochrome P450-inducible potency. *Cancer Sci.* **101**: 2525–2530. 2010.
10. Umemura T, Tasaki M, Kijima A, Okamura T, Inoue T, Ishii Y, Suzuki Y, Masui N, Nohmi T, and Nishikawa A. Possible participation of oxidative stress in causation of cell proliferation and *in vivo* mutagenicity in kidneys of *gpt* delta rats treated with potassium bromate. *Toxicology.* **257**: 46–52. 2009.
11. Ito N, Tamano S, and Shirai T. A medium-term rat liver bioassay for rapid *in vivo* detection of carcinogenic potential of chemicals. *Cancer Sci.* **94**: 3–8. 2003.
12. Butler WH. Long-term effects of phenobarbitone-Na on male Fischer rats. *Br J Cancer.* **37**: 418–423. 1978.
13. Takahashi O, Ohishi S, Fujitani T, Tanaka T, and Yoneyama M. Chronic toxicity studies of piperonyl butoxide in F344 rats: induction of hepatocellular carcinoma. *Fundam Appl Toxicol.* **22**: 293–303. 1994.

14. National Toxicological Program (NTP) Toxicology and carcinogenesis studies of acetaminophen (CAS No. 103-90-2) in F344/N rats and B6C3F<sub>1</sub> mice (feed studies). *Natl Toxicol Program Tech Rep Ser.* **394**: 1–274. 1993.
15. Wislocki PG, Miller EC, Miller JA, McCoy EC, and Rosenkranz HS. Carcinogenic and mutagenic activities of safrole, 1'-hydroxysafrole, and some known or possible metabolites. *Cancer Res.* **37**: 1883–1891. 1977.
16. National Toxicological Program (NTP) Toxicology and carcinogenesis studies of 5,5-diphenylhydantoin (phenytoin) (CAS No. 57-41-0) in F344/N rats and B6C3F<sub>1</sub> mice (feed studies). *Natl Toxicol Program Tech Rep Ser.* **404**: 1–303. 1993.
17. Kawamura Y, Hayashi H, Tajima O, Yamada S, Takayanagi T, Hori H, Fujii W, Masumura K, and Nohmi T. Evaluation of the genotoxicity of aristolochic acid in the kidney and liver of F344 *gpt* delta transgenic rat using a 28-day repeated-dose protocol: a collaborative study of the *gpt* delta transgenic rat mutation assay. *Genes and Environment.* **34**: 18–24. 2012.
18. Nohmi T, Suzuki T, and Masumura K. Recent advances in the protocols of transgenic mouse mutation assays. *Mutat Res.* **455**: 191–215. 2000.
19. Watanabe T, Katsura Y, Yoshitake A, Masataki H, and Mori T. IPAP: Image processor for analytical pathology. *J Toxicol Pathol.* **7**: 353–361. 1994.
20. Kanki K, Nishikawa A, Masumura K, Umemura T, Imazawa T, Kitamura Y, Nohmi T, and Hirose M. *In vivo* mutational analysis of liver DNA in *gpt* delta transgenic rats treated with the hepatocarcinogens N-nitrosopyrrolidine, 2-amino-3-methylimidazo [4,5-f] quinoline, and di (2-ethylhexyl) phthalate. *Mol Carcinog.* **42**: 9–17. 2005.
21. Toyoda-Hokaiwado N, Inoue T, Masumura K, Hayashi H, Kawamura Y, Kurata Y, Takamune M, Yamada M, Sanada H, Umemura T, Nishikawa A, and Nohmi T. Integration of *in vivo* genotoxicity and short-term carcinogenicity assays using F344 *gpt* delta transgenic rats: *in vivo* mutagenicity of 2,4-diaminotoluene and 2,6-diaminotoluene structural isomers. *Toxicol Sci.* **114**: 71–78. 2010.
22. Hibi D, Suzuki Y, Ishii Y, Jin M, Watanabe M, Sugita-Konishi Y, Yanai T, Nohmi T, Nishikawa A, and Umemura T. Site-specific *in vivo* mutagenicity in the kidney of *gpt* delta rats given a carcinogenic dose of ochratoxin A. *Toxicol Sci.* **122**: 406–414. 2011.
23. Kakehashi A, Ishii N, Shibata T, Wei M, Okazaki E, Tachibana T, Fukushima S, and Wanibuchi H. Mitochondrial prohibitins and septin 9 are implicated in the onset of rat hepatocarcinogenesis. *Toxicol Sci.* **119**: 61–72. 2011.
24. Kushida M, Sukata T, Uwagawa S, Ozaki K, Kinoshita A, Wanibuchi H, Morimura K, Okuno Y, and Fukushima S. Low dose DDT inhibition of hepatocarcinogenesis initiated by diethylnitrosamine in male rats: possible mechanisms. *Toxicol Appl Pharmacol.* **208**: 285–294. 2005.
25. Nagahara T, Okano J, Fujise Y, Abe R, and Murawaki Y. Preventive effect of JTE-522, a selective cyclooxygenase-2 inhibitor, on DEN-induced hepatocarcinogenesis in rats. *Biomed Pharmacother.* **64**: 319–326. 2010.
26. Ogiso T, Takematsu M, Tamano S, Tsuda H, and Ito N. Comparative effects of carcinogens on the induction of placental glutathione S-transferase-positive liver nodules in a short-term assay and of hepatocellular carcinomas in a long-term assay. *Toxicol Pathol.* **13**: 257–265. 1985.
27. Aiub CA, Gadermaier G, Silva IO, Felzenszwalb I, Pinto LF, Ferreira F, and Eckl P. N-nitrosodiethylamine genotoxicity evaluation: a cytochrome P450 induction study in rat hepatocytes. *GMR Genet Mol Res.* **10**: 2340–2348. 2011.
28. Basak R, Basu M, and Chatterjee M. Combined supplementation of vanadium and 1 $\alpha$ ,25-dihydroxyvitamin D3 inhibit diethylnitrosamine-induced rat liver carcinogenesis. *Chem-Biol Interact.* **128**: 1–18. 2000.
29. Tsuda H, Lee G, and Farber E. Induction of resistant hepatocytes as a new principle for a possible short-term *in vivo* test for carcinogens. *Cancer Res.* **40**: 1157–1164. 1980.
30. Fukushima S, Kinoshita A, Puatanachokchai R, Kushida M, Wanibuchi H, and Morimura K. Hormesis and dose-response-mediated mechanisms in carcinogenesis: evidence for a threshold in carcinogenicity of non-genotoxic carcinogens. *Carcinogenesis.* **26**: 1835–1845. 2005.
31. Bagnyukova TV, Tryndyak VP, Montgomery B, Churchwell MI, Karpf AR, James SR, Muskhelishvili L, Beland FA, and Pogribny IP. Genetic and epigenetic changes in rat preneoplastic liver tissue induced by 2-acetylaminofluorene. *Carcinogenesis.* **29**: 638–646. 2008.
32. Heflich RH, and Neft RE. Genetic toxicity of 2-acetylaminofluorene, 2-aminofluorene and some of their metabolites and model metabolites. *Mutat Res.* **318**: 73–114. 1994.
33. Schut HA, and Snyderwine EG. DNA adducts of heterocyclic amine food mutagens: implications for mutagenesis and carcinogenesis. *Carcinogenesis.* **20**: 353–368. 1999.
34. Shen LC, Chiang SY, Lin MH, Chung WS, and Wu KY. *In vivo* formation of N7-guanine DNA adduct by safrole 2',3'-oxide in mice. *Toxicol Lett.* **213**: 309–315. 2012.
35. Ross JA, and Leavitt SA. Induction of mutations by 2-acetylaminofluorene in *lacI* transgenic B6C3F1 mouse liver. *Mutagenesis.* **13**: 173–179. 1998.
36. Schaaper RM, Koffel-Schwartz N, and Fuchs RP. N-Acetoxy-N-acetyl-2-aminofluorene-induced mutagenesis in the *lacI* gene of *Escherichia coli*. *Carcinogenesis.* **11**: 1087–1095. 1990.
37. Xie XL, Wei M, Kakehashi A, Yamano S, Okabe K, Tajiri M, and Wanibuchi H. Dammar resin, a non-mutagen, induces oxidative stress and metabolic enzymes in the liver of *gpt* delta transgenic mouse which is different from a mutagen, 2-amino-3-methylimidazo [4,5-f] quinoline. *Mutat Res.* **748**: 29–35. 2012.
38. Ito N, Tsuda H, Tatematsu M, Inoue T, Tagawa Y, Aoki T, Uwagawa S, Kagawa M, Ogiso T, Masui T, Imaida K, Fukushima S, and Asamoto M. Enhancing effect of various hepatocarcinogens on induction of preneoplastic glutathione S-transferase placental form positive foci in rats—an approach for a new medium-term bioassay system. *Carcinogenesis.* **9**: 387–394. 1988.
39. Beamand JA, Price RJ, Phillips JC, Butler WH, Jones GD, Osimitz TG, Gabriel KL, Preiss FJ, and Lake BG. Lack of effect of piperonyl butoxide on unscheduled DNA synthesis in precision-cut human liver slices. *Mutat Res.* **371**: 273–282. 1996.
40. Muguruma M, Kawai M, Dewa Y, Nishimura J, Saegusa Y, Yasuno H, Jin M, Matsumoto S, Takabatake M, Arai K, and Mitsumori K. Threshold dose of piperonyl butoxide that induces reactive oxygen species-mediated hepatocarcinogenesis in rats. *Arch Toxicol.* **83**: 183–193. 2009.
41. Mengs U, Lang W, and Poch JA. The carcinogenic action of aristolochic acid in rats. *Arch Toxicol.* **51**: 107–119. 1982.

42. Mei N, Arlt VM, Phillips DH, Heflich RH, and Chen T. DNA adduct formation and mutation induction by aristolochic acid in rat kidney and liver. *Mutat Res.* **602**: 83–91. 2006.
43. Kang JS, Wanibuchi H, Morimura K, Gonzalez FJ, and Fukushima S. Role of CYP2E1 in diethylnitrosamine-induced hepatocarcinogenesis *in vivo*. *Cancer Res.* **67**: 11141–11146. 2007.

## In Vivo Genotoxicity of Methyleugenol in *gpt* Delta Transgenic Rats Following Medium-Term Exposure

Meilan Jin,<sup>\*,†</sup> Aki Kijima,<sup>\*</sup> Daisuke Hibi,<sup>\*</sup> Yuji Ishii,<sup>\*</sup> Shinji Takasu,<sup>\*</sup> Kohei Matsushita,<sup>\*</sup> Ken Kuroda,<sup>‡</sup> Takehiko Nohmi,<sup>‡</sup> Akiyoshi Nishikawa,<sup>§</sup> and Takasi Umemura<sup>\*,1</sup>

<sup>\*</sup>Division of Pathology, National Institute of Health Sciences, Tokyo 158-8501, Japan; <sup>†</sup>Tripod Preclinical Research Laboratories Inc., Nanjing, China; and <sup>‡</sup>Sciences of Genome Safety and <sup>§</sup>Biological Safety Research Center, National Institute of Health Sciences, Tokyo 158-8501, Japan

<sup>1</sup>To whom correspondence should be addressed at Division of Pathology, National Institute of Health Sciences, 1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan. Fax: +81 03 3700 1425. E-mail: [umemura@nihs.go.jp](mailto:umemura@nihs.go.jp).

Received June 20, 2012; accepted September 27, 2012

Methyleugenol (MEG), which is commonly used as a fragrance and flavoring agent, has been shown to induce hepatocellular tumors in rodents. However, the role of genotoxicity as a possible mechanism of action is not fully understood even though the DNA-reactive metabolite of MEG has been identified. In this study, a *gpt* delta transgenic rat model was used to clarify whether genotoxic mechanisms are involved in MEG-induced hepatocarcinogenesis following medium-term exposure. F344 *gpt* delta rats were subjected to repeated oral administration of MEG at dosages of 0, 10, 30, or 100 mg/kg (a carcinogenic dose) for 13 weeks. The relative weight of the liver of the male and female rats that were administered 100 mg/kg MEG and the absolute weight of the liver of the male rats that were administered 100 mg/kg MEG were significantly increased. In addition, the number and area of glutathione S-transferase placental form (GST-P) positive foci and proliferating cell nuclear antigen (PCNA) positive cell ratios in the hepatocytes were significantly increased in the male and female rats that were administered 100 mg/kg MEG compared with the control animals. In the *in vivo* mutation assays, a significant increase in the *gpt* and Spi<sup>-</sup> mutant frequencies was observed in both sexes at the carcinogenic dose. These results suggest the possible participation of genotoxic mechanisms in MEG-induced hepatocarcinogenesis.

**Key Words:** methyleugenol; *in vivo* genotoxicity; *gpt* delta rats.

Methyleugenol (3,4-dimethoxyallylbenzene; MEG) is a natural flavor present in many herbs and spices consumed at low levels in the human diet and has been approved for commercial use as a fragrance and flavoring agent. MEG is a member of the alkoxy-substituted allylbenzene family of chemicals, which include other naturally occurring substances, such as estragole and safrole. MEG is a hepatocarcinogen in F344 rats and B6C3F<sub>1</sub> mice at doses higher than 37 mg/kg, which is similar to the carcinogenic dose of other alkoxy-substituted allylbenzenes (National Toxicology Program [NTP], 2000). At the 69th meeting of the Joint FAO/WHO Expert Committee on Food Additives (JECFA), a safety assessment of flavoring substances, including

alkoxy-substituted allylbenzenes, was reported to be pending because the underlying mechanisms of their carcinogenic effects remained unclear (FAO/WHO, 2008). Data regarding the underlying modes of action in MEG-induced hepatocarcinogenesis are important for establishing an overall risk assessment of the flavoring agents classified as alkoxy-substituted allylbenzenes.

Zhou *et al.* (2007) reported that MEG forms adducts in human cellular DNA. Other alkoxy-substituted allylbenzenes, such as safrole and estragole, also form specific DNA adducts (Ishii *et al.*, 2011; Miller and Miller, 1983), which may trigger genotoxicity in the rat liver (Jin *et al.*, 2011; Suzuki *et al.*, 2012). As such, it is highly probable that MEG has the potential to be genotoxic *in vivo* in the rat liver. However, MEG was not shown to be mutagenic in *Salmonella typhimurium* TA98, TA100, TA1535, and TA1537 (NTP, 2000). Several MEG metabolites have been reported to be activated to DNA-reactive mutagens in *S. typhimurium* following incorporation of increased sulfation capacity and may be involved in carcinogenicity, organ toxicity, and immune reactions (Cartus *et al.*, 2012; Herrmann *et al.*, 2012). The results of conventional genotoxicity tests, such as sister chromatid exchange (SCE), the micronucleus test, and the comet assay, have not been consistent (Ding *et al.*, 2011; NTP, 2000).

The *gpt* delta transgenic rat developed by Nohmi *et al.* (1996) is recognized as an *in vivo* mutation assay model that is capable of detecting point mutations by 6-thioguanine (6-TG) selection and deletion mutations by Spi<sup>-</sup> selection (Hayashi *et al.*, 2003; Masumura *et al.*, 2003; Umemura *et al.*, 2009). Quantitative analyses of glutathione S-transferase placental form (GST-P) positive foci can be performed in *gpt* delta transgenic rats and conventional non-transgenic rats (Toyoda-Hokaiwado *et al.*, 2010). The *gpt* delta rat animal model may be a promising tool for investigating the comprehensive toxicities, including the genotoxicity and carcinogenicity, of chemical agents in target organs. We confirmed the availability of a medium-term animal model using *gpt* delta rats that demonstrated hepatotoxicity, hepatocarcinogenicity, and genotoxicity following exposure to safrole in the target organ (Jin *et al.*, 2011).